Stevens-Johnson Syndrome Antimicrobial

checkorphan
Learn more about:
Toxic Epidermal Necrolysis
Related Clinical Trial
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren’s Syndrome, and Graft Vs Host Disease LYell SYndrome MEsenchymal Stromal Cells Treatment Severe Bullous Drug Eruption and Filgrastim Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Severe Cutaneous Adverse Reactions in Thailand Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Stevens-Johnson Syndrome Antimicrobial Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye G-CSF in the Treatment of Toxic Epidermal Necrolysis Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Topical Infliximab in Autoimmune Eyes With Keratoprosthesis HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction Drug Reactions Sampling (COLLECTIONTOXIDERMIES) Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis NATIENS: Optimal Management and Mechanisms of SJS/TEN

Brief Title

Stevens-Johnson Syndrome Antimicrobial

Official Title

Stevens-Johnson Syndrome Associated With Antimicrobial

Brief Summary

      Steven-Johnson's syndrome, or great multiform erythema, appears as a systemic disturbance,
      with skin involvement and mucous membranes, related to several factors, such as, viral or
      bacterial infections and mainly the administration of medicines, in general painkillers and
      antibiotics. The objective of this work is report the emergence of ulcerative vesicle -bubble
      chronic disease in areas of lips, gum, tongue and genital mucous membrane in a 26 year-old
      patient, leucoderma and masculine gender, in treatment of breathing infection with
      sulfametoxazol-trimetropima, having been diagnosed as syndrome of Steven-Johnson.

Detailed Description

      Among the serious medicaments reactions, there are as great representative the Mucocutaneous
      Disorders immunological mediated. Steven-Johnson's syndrome, or great multiform erythema,
      appears as a systemic disturbance, with skin involvement and mucous membranes, related to
      several factors, such as, viral or bacterial infections and mainly the administration of
      medicines, in general painkillers and antibiotics. The objective of this work is report the
      emergence of ulcerative vesicle -bubble chronic disease in areas of lips, gum, tongue and
      genital mucous membrane in a 26 year-old patient, leucoderma and masculine gender, in
      treatment of breathing infection with sulfametoxazol-trimetropima, having been diagnosed as
      syndrome of Steven-Johnson.

Study Type

Observational

Condition

Stevens-Johnson Syndrome

Study Arms / Comparison Groups

 1
Description:  Sick

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment

1

Start Date

August 2008

Completion Date

December 2008

Primary Completion Date

August 2008

Eligibility Criteria

        Inclusion Criteria:

          -  Stevens-Johnson syndrome associated with antimicrobial

        Exclusion Criteria:

          -  Not sick

Gender

Male

Ages

20 Years - 60 Years

Accepts Healthy Volunteers

No

Contacts

Edwaldo Dr Dourado, Doctor, ,

Location Countries

Brazil

Location Countries

Brazil

Administrative Informations

NCT ID

NCT00844038

Organization ID

SSJ1

Secondary IDs

558187121279

Study Sponsor

University of Pernambuco

Study Sponsor

Edwaldo Dr Dourado, Doctor, Principal Investigator, University of Pernambuco

Verification Date

February 2009